Corcept Therapeutics (United States)

Recent papers from Corcept Therapeutics (United States)

1. Phase 1b study of miricorilant in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH)Hepatology · 2026
2. 0055Prevalence of Endogenous Hypercortisolism in Individuals With Resistant Hypertension Stratified by Kidney Function: Results From the MOMENTUM StudyAmerican Heart Journal · 2026
3. Neuropathological Effects of Early Maternal Separation are Prevented by CORT113176, A Glucocorticoid Receptor ModulatorCellular and Molecular Neurobiology · 2026
4. 161P Real-world comparative effectiveness of nab-paclitaxel and standard of care chemotherapies in patients with platinum-resistant ovarian cancer (COMPASS 2.0)ESMO Open · 2026
5. SYNERGY: A phase 1b/2 study of nenocorilant, a selective glucocorticoid receptor antagonist, plus nivolumab in patients with advanced solid malignancies.Journal of Clinical Oncology · 2026
6. TRIDENT: A phase 2 study of relacorilant plus nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic ductal adenocarcinoma.Journal of Clinical Oncology · 2026
7. Overall survival subgroup analyses for prior taxane use in the phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72, APGOT-Ov10, LACOG-0223, and ANZGOG-2221/2023).Journal of Clinical Oncology · 2026
8. Signaling Under Stress: Targeting the Glucocorticoid Receptor in CancerCancer Research · 2026
9. Resistant hypertension, hyperaldosteronism, and the emerging understanding of hypercortisolismCurrent Opinion in Cardiology · 2026
10. TMPRSS2-ERG confers resistance of prostate cancer to antiandrogensEMBO Molecular Medicine · 2026
11. Nivolumab plus ipilimumab for chemotherapy-refractory metastatic castration-resistant prostate cancer: results from the randomized portion of the phase 2 CheckMate 650 trialNature Communications · 2026
12. Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trialThe Lancet · 2026
13. Investigating Endogenous Hypercortisolism Prevalence in a U.S. Population With Resistant HypertensionJACC Advances · 2026
14. Comparative outcomes of nab-paclitaxel and paclitaxel in platinum-resistant ovarian cancer (COMPASS)Gynecologic Oncology · 2025
15. Evaluation of the Pharmacokinetics, Disposition, and Metabolism of Miricorilant, a Novel Glucocorticoid Receptor Modulator for the Treatment of Metabolic Dysfunction‐Associated Steatohepatitis in Nonclinical and Clinical StudiesThe Journal of Clinical Pharmacology · 2025
16. Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone TreatmentDiabetes Care · 2025
17. 70O Phase III results of relacorilant + nab-paclitaxel vs nab-paclitaxel in platinum-resistant ovarian cancer (PROC) (ROSELLA, GOG-3073, ENGOT-ov72): Secondary endpointsESMO Open · 2025
18. Prevalence of Hypercortisolism in Difficult-to-Control Type 2 DiabetesDiabetes Care · 2025
19. Advancing Alzheimer's disease pharmacotherapy: efficacy of glucocorticoid modulation with dazucorilant (CORT113176) in preclinical mouse modelsBritish Journal of Pharmacology · 2025
20. TMPRSS2-ERG confers resistance to antiandrogens: mechanism and therapeutic implications2025